trial

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

NCTId NCT01175135
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 259 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2011-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
259 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2010-10
Primary completion
2011-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PF-02545920Risperidone

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

46 total
Little Rock, United StatesAnaheim, United StatesEscondido, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesLong Beach, United StatesOrange, United StatesParamount, United StatesParamount, United StatesSan Diego, United StatesSanta Ana, United States

Linked catalysts

1
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In T — primary completion2011-08

Facts & assertions

4 sourced
Enrollment
259
Phase
PHASE2
Primary Completion Date
2011-08
Status
COMPLETED
relationships
The graph out of here
drug
PF-02545920
drug
Risperidone
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication